Interestingly, adoptive transfer of WT T cells into Rag-1?/?/Ang-II mice resulted in increased numbers of immature platelets, which constitutes a more active platelet population i

Interestingly, adoptive transfer of WT T cells into Rag-1?/?/Ang-II mice resulted in increased numbers of immature platelets, which constitutes a more active platelet population i.e. mice reconstituted with WT-derived T cells, suggesting T cell IL-6 mediates the thrombotic abnormalities associated Ang-II HTN. Interestingly, adoptive transfer of WT T cells into Rag-1?/?/Ang-II mice resulted in increased numbers of immature platelets, which constitutes a more active platelet population i.e. pro-thrombotic and pro-inflammatory. To translate our findings, we used clinical samples to demonstrate that IL-6 also predisposes platelets to an VAL-083 conversation with collagen receptors, thereby increasing the propensity for platelets to aggregate and cause thrombosis. In VEGFC summary, we provide compelling evidence for the involvement of IL-6, IL-6R and T cell-dependent IL-6 signaling in Ang-II induced thrombo-inflammation, which may provide new therapeutic possibilities for drug discovery programs for the management of HTN. a cardio- and cerebrovascular risk factor, pre-disposing hypertensive patients to pro-inflammatory and pro-thrombotic vascular dysfunction,1C3 Furthermore, it is known that this pleiotropic molecule angiotensin II (Ang-II), the main effector of the renin-angiotensin system (RAS), plays a role in mediating elevated blood pressure and promoting vascular and endothelial cell dysfunction, hypertrophy and oxidative stress.1,4C10 Abnormalities in the functions of circulating VAL-083 immune cells which accompany the chronically elevated blood pressure associated with Ang-II5,7C9 and other models of HTN (e.g. high salt diet model9, 10 and the spontaneous HTN model11, 12) has been well-documented. However, it is not the elevated blood pressure that is the driving factor for thrombosis,9,13 but rather Ang-II itself. T cells play an important role in adaptive immune responses and we and others have shown a major role for these cells in Ang-II induced HTN.5,9,14,15 Additionally, immunodeficient mice lacking both T- and B-lymphocytes (Rag-1 knockout [Rag-1?/?]) VAL-083 exhibit improvement in vasomotor dysfunction and leukocyte accumulation,9,15C17 and adoptive transfer of T cells, but not B cells, into Rag-1?/? mice restored the pro-thrombotic phenotype induced by Ang-II. These data confirm the major role that T cells play in mediating Ang-II induced accelerated microvascular thrombosis,9 however the mechanism by which T-cells induces this pro-thrombotic environment remains unknown. Both Ang-II-induced HTN and T cells have a very strong relationship with the cytokine IL-6, which exerts its biological activities through two molecules: IL-6R (also known as IL-6R, gp80 or CD126) and gp130 (also referred to as IL-6R or CD130).18C21 In the context of Ang-II HTN, reports have shown IL-6 to contribute to increased blood pressure, inflammatory cell recruitment, endothelial dysfunction,18,22C25 with a deficiency in either IL-6 or T cells providing protection.26,27 However, not only is the role that IL-6 plays in Ang-II-mediated thrombosis unknown, the actual role that T-cell-derived IL-6 signaling plays in the thrombo-inflammatory responses associated with Ang-II remains poorly defined. Thus, we herein tested the hypothesis that this chronic pro-thrombotic phenotype associated with Ang-II induced HTN is usually mediated by a mechanism that is dependent on both T cells and IL-6. Our novel data reveal that IL-6 plays a major role in the T cell-dependent thrombo-inflammatory responses elicited by chronic Ang-II administration, with contributions by both IL-6R and gp130 receptors. We also found that IL-6 is able to potentiate platelets, pre-disposing them to stimulation/activation of the collagen receptor GPVI and contributing to platelet aggregation (by increasing GPIIbIIIa expression). In summary, T cell dependent IL-6 signaling mediates microvascular thrombotic and inflammatory VAL-083 responses associated with chronically elevated levels of Ang-II. Our compelling data suggests that new therapeutic strategies for drug discovery programs based on T cell dependent IL-6 signaling pathways may provide a previously unknown therapeutic strategy for the management of the thrombo-inflammatory complications that accompany HTN. Materials and methods. All data supporting the findings of this study are available within the article and its Supplementary files, or are available from the corresponding author upon affordable request. All studies were done blinded and performed Male wild-type (WT, C57BL/6), IL-6 deficient (IL-6?/? B6.129S6-IL6tml Kopf,), and Rag-1 deficient (Rag-1?/?. B6;129S7-Rag1tmMom/J) mice were purchased from Jackson Laboratory (Bar Harbor, ME) at 6C8 weeks of age. Housing and all of the animal experiments were performed in accordance with experimental procedures approved by the Louisiana State University Health Science Center Institutional Animal Care and Use Committee and in compliance with.